Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
453 results about "Antidepressant" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Antidepressants are medications used to treat major depressive disorder, some anxiety disorders, some chronic pain conditions, and to help manage some addictions. Common side-effects of antidepressants include dry mouth, weight gain, dizziness, headaches, and sexual dysfunction. Most types of antidepressants are typically safe to take, but may cause increased thoughts of suicide when taken by children, adolescents, and young adults. A discontinuation syndrome can occur after stopping any antidepressant which resembles recurrent depression.
Topical compositions and methods for treating pain
InactiveUS6638981B2Avoid painComposition is stableBiocideNervous disorderNR1 NMDA receptorPreventing pain
Owner:EPICEPT CORP
Smoking cessation treatments using naltrexone and related compounds
InactiveUS6541478B1Reduce weight gainPrevent relapseBiocideNervous disorderOpioid antagonistAntianxiety Agent
Nicotine dependency is treated by administration of an opioid antagonist. In some embodiments, rapid or ultra rapid detoxification techniques include using a combination of an effective amount of an opioid antagonist such as nalmefene, naloxone or naltrexone or a mixture of any one of these, and either clonidine or related compounds either while awake, or while under sedation or anesthesia, followed by continued administration of an effective amount of an opioid antagonist with or without agents that enhance nicotine dependency treatment. Persons are also treated for nicotine dependency with more gradual detoxification methods using administration of a combination of an effective amount of an opioid antagonist such as nalmefene, naloxone, naltrexone, or a mixture of any of these, and an effective amount of agents used to treat nicotine withdrawal including nicotine, such as that delivered by a nicotine patch, nicotine chewing gum, nicotine inhaler or other methods for delivering nicotine, antidepressants and antianxiety agents, and / or clonidine and related compounds. Administration of an effective amount of an opioid antagonist to prevent relapse, attenuate craving, and reduce weight gain during and after treatment for nicotine dependency is continued in some embodiments.
Owner:YALE UNIV
Pain relief lollipop compositions and methods
InactiveUS20090191257A1Without pain and invasivenessFast pain reliefOrganic active ingredientsNervous disorderGabapentinOpioid Agonist
A pain relief lollipop comprises a candy matrix comprising (a) an opioid agonist, (b) an N-methyl-D-aspartate receptor antagonist different from the opioid agonist, (c) gabapentin, or a pharmaceutically acceptable salt thereof, and, optionally, a muscle relaxant, sedative, anxiolytic, and / or antidepressant. A patient can self-administer small amounts of the pain relief drug as needed by simply licking or sucking on the lollipop in response to his subjective experience of pain.
Owner:INNOVATIVE PHARMA
Topical compositions and methods for treating pain
InactiveUS20030082214A1Treating and preventing painAvoid painBiocideNervous disorderPreventing painNR1 NMDA receptor
Topical compositions and methods for treating pain. The invention provides oil-in-water emulsions comprising an antidepressant; an NMDA-receptor antagonists; a lipophilic component; water; and a surfactant. The compositions induce a local-anesthetic effect when topically administered to intact skin thereby treating or preventing pain, for example, neuropathic pain.
Owner:EPICEPT CORP
Bupropion formulation for sustained delivery
InactiveUS20050112198A1Improve stabilityProvide controlPharmaceutical non-active ingredientsPill deliveryAdditive ingredientPharmaceutical formulation
Disclosed is a pharmaceutical formulation for the stabilization and sustained delivery of an active pharmaceutical ingredient, such as the antidepressant, bupropion.
Owner:MURTY PHARMA
Antidepressant oral pharmaceutical compositions
Novel enteric compositions suitable for oral administration comprising Duloxetine or its pharmaceutical derivatives thereof and methods for preparing such compositions are disclosed. Such compositions contain a core consisting of a Duloxetine or its pharmaceutical derivatives thereof, the said core comprised of a pharmaceutically inert nuclei and the Duloxetine or its pharmaceutical derivatives thereof compressed together, an intermediate and an enteric layer. Duloxetine or its pharmaceutical derivatives thereof may be any pharmaceutically acceptable prodrug, salt, solvate or derivative of Duloxetine. The novel compositions prepared according to the present invention have enhanced stability and bioavailability.
Owner:COMPANY WOCKHARDT THE
Adjunctive Therapy for Depression
This invention is directed to a method of treating depression in a subject, comprising the step of administering a therapeutically effective amount of a conventional antidepressant and, in addition, administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt or ester thereof wherein Rx is a member Rx selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, halogen selected from F, Cl, Br and I, alkoxy containing 1 to 3 carbon atoms, nitro, hydroxy, trifluoromethyl, and thioalkoxy containing 1 to 3 carbon atoms; x is an integer of 1 to 3, with the proviso that R may be the same or different when x is 2 or 3; R1 and R2 can be the same or different each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, arylalkyl, cycloalkyl of 3 to 7 carbon atoms; R1 and R2 can be joined to form a 5 to 7-membered heterocycle substituted with a member selected from the group consisting of hydrogen, alkyl, and aryl groups, wherein the cyclic compound can comprise 1 to 2 nitrogen atoms and 0 to 1 oxygen atom, wherein the nitrogen atoms are not directly connected with each other or with the oxygen atom.
Owner:BIOPHARM
Aralkyl-alcohol peiperazine derivatives adn their uses as antidepressant
Aryl alkanol piperazine derivatives of the formula and pharmaceutical compositions comprising the same. Also disclosed are methods for treating depression using the pharmaceutical compositon. Compounds of the invention have excellent dual inhibitory actions to the uptake of the mono-amines neurotransmitter, good antidepressant activities and minor side effects.
Owner:SHANGHAI INST OF PHARMA IND
Adjunctive therapy for depression
Owner:BIOPHARM
Composition and Method for Treatment of Depression and Psychosis in Humans
ActiveUS20140018348A1Eliminate side effectsReduce side effectsBiocideNervous disorderPsychosisAntagonist
Compositions and methods tor the treatment of depression and psychoses in humans are disclosed. More particularly, the invention is directed to formulations containing antipsychotic and / or antidepressant medications and also containing an NMPAR antagonist. The present invention is also directed to methods for the treatment of humans suffering from depression and other psychoses, including, schizophrenia, by administration of the inventive compositions in antidepressant and / or antipsychotic effective amounts.
Owner:GLYTECH
Treatment of pain
A method of treating pain by the co-administration of an antidepressant together with one or more precursors or inducers of neurotransmitters, particularly amino acids selected from L-phenylalanine, L-tyrosine, L-tryptophan and L-DOPA.
Owner:AMARIN NEUROSCI
Composition and method for compounded therapy
The present embodiments relate to topically delivered compounded medications. A transdermal cream may provide the effective topical administration of multiple medications simultaneously; may include low concentrations of local anesthetics, a NSAID, an anticonvulsant, and / or other active ingredients; and may include lidocaine, prilocaine, meloxicam, and lamotrigine and / or topiramate. Alternatively, the transdermal cream may include a lidocaine / prilocaine base cream to which is added a fine powder of one or more ground up medications to form a compounded medication. The compounded medication in powder form may be generated from grinding up tablets of NSAIDs, anticonvulsants, nerve depressants, antidepressants, muscle relaxants, NMDA receptor antagonists, opiate or opioid agonists, and / or other agents. The compounded medication in powder form may include meloxicam, lamotrigine, topiramate, other active ingredients, and DMSO or Sterile Water for Irrigation. In another aspect, the present embodiments relate to methods of compounding medications and transdermal creams or gels.
Owner:CMPD LICENSING
Acamprosate formulations, methods of using the same, and combinations comprising the same
Embodiments disclosed herein generally relate to acamprosate formulations, methods of use of the formulations, to methods of using the formulations in combination with at least one other medication, and to combination products and compositions comprising the formulations and at least one other medication, such as neuroleptic (antipsychotic) and / or antidepressant drugs.
Owner:SYNCHRONEURON
Method of administering antidepressant dosage form
InactiveUS6440457B1Constant drug levelFacilitated releaseOrganic active ingredientsBiocideDosage formAntidepressant
The invention pertains to a dosage form 10 and to administering an antidepressant medicament 16 for an extended period of time in a rate-known dose.
Owner:ALZA CORP
Combination drug therapy to treat obesity
InactiveUS20050143350A1Undesirable weight gainGood for weight lossBiocideMetabolism disorderCombination drug therapyAnticholinesterase Agents
Provided are methods of achieving desirable weight loss in an overweight or obese individual by administering at least one anticholinesterase agent and at least one antidepressant. The invention also provides for pharmaceutical compositions and kits for simultaneous delivery of at least one anticholinesterase agent and at least one antidepressant.
Owner:THERAKOS INC
Combination therapy for pain in painful diabetic neuropathy
InactiveUS20100256179A1Improve treatmentBiocideNervous disorderNR1 NMDA receptorCombined Modality Therapy
A method for treating pain in painful diabetic neuropathy comprises administering in combination a first agent that comprises a compound as defined herein, illustratively lacosamide, and a second agent effective to provide enhanced treatment of pain, by comparison with the first agent alone. The second agent illustratively comprises an analgesic, an anticonvulsant, an antidepressant or an NMDA receptor antagonist.
Owner:UCB SA
Combinations of Eszopiclone and an Antidepressant
One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone. The second component of the pharmaceutical composition is an antidepressant. The present invention also relates to a method of treating menopause, perimenopause, mood disorders, anxiety disorders, and cognitive disorders.
Owner:SEPACOR INC
Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical
Methods and compositions are provided for treating neuropsychiatric disorders such as schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, and bipolar disorder. The methods entail administering to a patient diagnosed as having a neuropsychiatric disorder (e.g., schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia bipolar disorder, etc.) or as at risk for a neuropsychiatric disorder a benzoic acid, benzoic acid salt, and / or benzoic acid derivative, and / or a sorbic acid, sorbic acid salt, and / or sorbic acid derivative, in combination with a neuropharmacological agent (e.g., an antipsychotic, an antidepressant, medications for attention deficit and hyperactivity disorder, cognitive impairment, or dementia, etc.) where the benzoic acid, benzoic acid salt, or benzoic acid derivative, and / or a sorbic acid, sorbic acid salt, and / or sorbic acid derivative, is in an amount sufficient to increase the efficacy of the neuropharmacological agent.
Owner:LOS ANGELES BIOMEDICAL RES INST AT HARBOR UCLA MEDICAL CENT
.beta.3 adrenergic agonists
InactiveUS6730792B2Reduce the possibilityBiocidePowder deliveryAdrenergic receptor agonistsEnergy expenditure
Owner:ELANCO US INC
Application of tetrandrine in preparation of drug for prevention and/or treatment of depression
ActiveCN102274227AShorten immobility timeSignificant preventionOrganic active ingredientsNervous disorderDiseaseSide effect
The invention discloses novel application of tetrandrine in preparation of a drug for prevention, alleviation and / or treatment of depression. A result of a test shows that tetrandrine has obvious anti-depression curative effects, can produce effects fast and has few toxic and side effects, and thus is a safe, efficient and stable anti-depression drug of which a preparation process is simple. Therefore, tetrandrine is suitable for industrialized production and is easy to be popularized. The invention provides a novel drug source for prevention and treatment of depression and its concurrent diseases, disorder or illnesses.
Owner:TIANJIN UNIV OF TRADITIONAL CHINESE MEDICINE
6-Fluorobicyclo[3.1.0]hexane derivatives
InactiveUS20050119345A1Highly effective for treating depressive symptomOrganic active ingredientsBiocideAlkoxy groupAcyl group
An antidepressant comprising, as an active ingredient, a compound having an antagonistic effect on group II metabotropic glutamate receptors, as well as a 2-amino-3-alkoxy-6-fluoro-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative of Formula [I]: [wherein R1 and R2, which may be the same or different, each represent a hydroxyl group, a C1-10 alkoxy group, etc.; R3 represents a C1-10 acyl group, a C1-6 alkoxy-C1-6 acyl group, etc.; and R4 and R5, which may be the same or different, each represent a hydrogen atom, a C1-10 alkyl group, etc.] or a pharmaceutically acceptable salt or hydrate thereof.
![6-Fluorobicyclo[3.1.0]hexane derivatives](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/279e3e93-8b91-4412-bdc3-51afad137f73/US20050119345A1-20050602-D00001.png "6-Fluorobicyclo[3.1.0]hexane derivatives")
![6-Fluorobicyclo[3.1.0]hexane derivatives](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/279e3e93-8b91-4412-bdc3-51afad137f73/US20050119345A1-20050602-D00002.png "6-Fluorobicyclo[3.1.0]hexane derivatives")
![6-Fluorobicyclo[3.1.0]hexane derivatives](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/279e3e93-8b91-4412-bdc3-51afad137f73/US20050119345A1-20050602-C00001.png "6-Fluorobicyclo[3.1.0]hexane derivatives")
Owner:TAISHO PHARMACEUTICAL CO LTD
Application of 5'-methoxy-3',4'-methylenedioxy cinnamic acid isobutyl amide in preparing antidepressant medicaments
ActiveCN102240281ASignificantly antagonizes body temperature dropSignificantly antagonizes drooping eyelidsNervous disorderPill deliveryMethylenedioxyCinnamic acid
The invention belongs to the field of traditional Chinese medicine preparation, and relates to application of an amide compound 5'-methoxy-3',4'-methylenedioxy cinnamic acid isobutyl amide extracted from plants in preparing antidepressant medicaments.
Owner:TIANJIN TASLY PHARMA CO LTD
Pharmaceutical compositions for treating pain associated with dysmenorrhea
InactiveUS20150313892A1Reduced plasma concentrationEfficient managementBiocidePeptide/protein ingredientsMolecular entityN-methyl-D-aspartate Receptor Antagonists
Pain associated with primary and secondary dysmenorrhea is relieved in a human suffering there from by administering to the human a pain relieving amount of a synergistically acting sub-therapeutic combination of a nontoxic N-methyl-D-aspartate receptor antagonist such as dextromethorphan, magnesium, dextrorphan, ketamine or pharmaceutically acceptable salt thereof, tramadol or its analog such as recemic tramadol or an analogously acting molecular entity or pharmaceutically acceptable salt thereof, and an anticonvulsant and / or a tricyclic anti-depressant or pharmaceutically acceptable salt thereof, and optionally in sustained release dosage form.
Owner:TRINITY LAB INC
Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
The present invention is a method for the treatment of depression comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-fused heterocycle sulfamide derivatives of formula (I) and formula (II) as herein defined. The present invention is directed to a method for the treatment of depression, which includes mono-therapy and alternatively, co-therapy with at least one antidepressant.
Owner:JANSSEN PHARMA NV
Method of promoting smoking cessation
InactiveUS20040102440A1Enhance smoking-cessation promoting effectFacilitating cessationBiocideNervous disorderOpioid antagonistSmoking cessation
Disclosed is a method of promoting smoking cessation in a human comprising administration to the human an effective amount of reboxetine in combination with the administration of a smoking-cessation enhancing agent. Also disclosed is a composition for administration to a human for promoting smoking cessation comprising reboxetine and smoking-cessation enhancing agent. Examples of the smoking-cessation enhancing agents include nicotine, an antidepressant, a nicotine receptor antagonist, and an opioid antagonist.
Owner:PHARMACIA & UPJOHN CO
Compositions with enhanced oral bioavailability
InactiveUS20030211072A1Low toxicityImprove oral bioavailabilityBiocidePowder deliveryDendrimerTolerability
The present invention describes the use of polysaccharides, surfactants, and dendrimers as bioavailability enhancers for oral pharmaceutical compositions. These substances exhert an inhibitory action of the gastrointestinal pump efflux proteins, such as the P-glycoprotein and the MDR protein, responsible for poor drug bioavailability and multidrug resistance. The formulations herein described comprise a medicinally active substance in association with said polysaccharides, surfactants, and dendrimers. They are well tolerated, are not absorbed by the gastrointestinal tract, and increase the bioavailability and the activity of orally administered medicaments, like, e.g. antineoplastic, antiviral, antibiotic, or antidepressant medicaments.
Owner:EURAND INT
Detection of antidepressant induced mania
Methods and kits for assessing the susceptibility of a patient to antidepressant-induced mania are described. The method involves testing a sample from a patient for the presence of the s variant of the 5HTTLPR polymorphism in the 5HTT gene. The presence of this s variant indicates that the patient is more susceptible to antidepressant-induced mania.
Owner:CENT FOR ADDICTION & MENTAL HEALTH
Treatment of psychological and cognitive disorders using a cholesterol -lowering agent in combination with an antidepressant
InactiveUS20060039890A1Reduce severityIncreased membrane fluidityBiocideNervous disorderCholesterolCognitive diseases
Owner:THE MCLEAN HOSPITAL CORP
Methods and formulations for making pharmaceutical compositions containing bupropion
InactiveUS20060099260A1Organic active ingredientsNervous disorderPh independentPharmaceutical formulation
Embodiments of the invention generally provide pharmaceutical drug compositions, methods of preparing oral drug compositions, such as extended release dosage compositions, and methods for treating antidepressant or smoking cessation. In one aspect, the invention provides a pharmaceutical formulation comprising a core, including bupropion and its salt derivatives, and a coating. The coating may include from about 5% to about 99% by weight of the coating of a pharmaceutically acceptable pH-independent polymer. The coating may further include from about 0.001% to about 30% by weight of the coating of a surfactant. In another aspect, the invention provides methods for preparing and administering a pharmaceutical composition in oral dosage form, such as a tablet.
Owner:BIOKEY
Pharmaceutical combination with depression resistance and angst resistance effect and method of preparing the same
The invention discloses a Chinese medicinal composition with the effects of antidepressant and anti-anxiety, and belongs to the field of Chinese traditional medicines. The Chinese medicinal composition comprises (by weight parts) radix bupleuri 6-15, cape jasmine fruit 5-15 or paeonia suffruticosa bark 5-20, and angelica sinensis 3-15 or ligusticum chuanxiong 3-15; and can be prepared into any conventional oral preparations. Different ministerial drugs and adjuvant drugs are added according to different subjects to better exert therapeutic effect. The inventive composition has the effects of antidepressant and anti-anxiety; and can be used for relieving depression and anxiety with the advantages of definite therapeutic effect and rapid drug effect. The inventive composition can also be used for relieving headache, palpitation, insomnia and melancholia.
Owner:SHENZHEN TONIC MEDICINE TECH
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com